PMID- 37754530
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20231003
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 30
IP  - 9
DP  - 2023 Sep 15
TI  - Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and 
      HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis.
PG  - 8444-8463
LID - 10.3390/curroncol30090615 [doi]
AB  - Despite the development of HER2-targeted drugs, achieving favorable outcomes for 
      patients with HR+/HER2+MBC remains challenging. This study utilized Bayesian 
      Network Meta-analysis to compare the efficacy and safety of anti-HER2 combination 
      regimens. The primary analysis focused on progression-free survival (PFS), while 
      secondary analyses included objective response rate, overall survival (OS) and 
      the incidence rate of grade 3/4 adverse events (AEs). A comprehensive search 
      across seven databases identified 25 randomized controlled trials for inclusion 
      in this meta-analysis. For patients eligible for endocrinotherapy, our findings 
      revealed that dual-target combined endocrine therapy, such as 
      Her2-mAb+Her2-mAb+Endo (HR = 0.38; 95%CrI: 0.16-0.88) and Her2-mAb+Her2-tki+Endo 
      (HR = 0.45; 95%CrI: 0.23-0.89), significantly improved PFS compared to endocrine 
      therapy alone. According to the surface under the cumulative ranking curves 
      (SUCRAs), Her2-mAb+Her2-mAb+Endo and Her2-mAb+Her2-tki+Endo ranked highest in 
      terms of PFS and OS, respectively. For patients unsuitable for endocrine therapy, 
      anti-HER2 dual-target combined chemotherapy, such as Her2-mAb+Her2-mAb+Chem (HR = 
      0.76; 95%CrI: 0.6-0.96) and Her2-mAb+Her2-tki+Chem (HR = 0.48; 95%CrI: 
      0.29-0.81), demonstrated significant improvements in PFS compared to 
      Her2-mAb+Chem. The results were the same when compared with Her2-tki+Chem. 
      According to the SUCRAs, Her2-mAb+Her2-tki+Chem and Her2-mAb+Her2-mAb+Chem ranked 
      highest for PFS and OS, respectively. Subgroup analyses consistently supported 
      these overall findings, indicating that dual-target therapy was the optimal 
      approach irrespective of treatment line.
FAU - Wu, Xian-Meng
AU  - Wu XM
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Southeast University, Nanjing 210009, China.
FAU - Qian, Yong-Kang
AU  - Qian YK
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Southeast University, Nanjing 210009, China.
FAU - Chen, Hua-Ling
AU  - Chen HL
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Southeast University, Nanjing 210009, China.
FAU - Hu, Chen-Hua
AU  - Hu CH
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Southeast University, Nanjing 210009, China.
FAU - Chen, Bing-Wei
AU  - Chen BW
AUID- ORCID: 0000-0003-0159-3699
AD  - Department of Epidemiology and Health Statistics, School of Public Health, 
      Southeast University, Nanjing 210009, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20230915
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/drug therapy
MH  - Bayes Theorem
MH  - Network Meta-Analysis
MH  - Databases, Factual
MH  - Progression-Free Survival
PMC - PMC10528081
OTO - NOTNLM
OT  - Bayesian network meta-analysis
OT  - HER2-positive
OT  - HR-positive
OT  - metastatic breast cancer
OT  - targeted therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/27 12:41
MHDA- 2023/09/28 06:43
PMCR- 2023/09/15
CRDT- 2023/09/27 08:55
PHST- 2023/07/16 00:00 [received]
PHST- 2023/09/09 00:00 [revised]
PHST- 2023/09/12 00:00 [accepted]
PHST- 2023/09/28 06:43 [medline]
PHST- 2023/09/27 12:41 [pubmed]
PHST- 2023/09/27 08:55 [entrez]
PHST- 2023/09/15 00:00 [pmc-release]
AID - curroncol30090615 [pii]
AID - curroncol-30-00615 [pii]
AID - 10.3390/curroncol30090615 [doi]
PST - epublish
SO  - Curr Oncol. 2023 Sep 15;30(9):8444-8463. doi: 10.3390/curroncol30090615.